Current recommendations for the management of bladder cancer: Drug therapy

Drugs

Volumn 53, Issue 3, 1997, Pages 404-414

  Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BROPIRIMINE; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; INTERFERON; METHOTREXATE; MITOMYCIN; THIOTEPA; VERAPAMIL; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; CYSTITIS; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; RECURRENCE RISK; SEPSIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR;

EID: 0030990609     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753030-00005     Document Type: Article

References (67)

1. Incidence of cancer in the Netherlands: 1992. Netherlands Cancer Registry, Utrecht, 1992
2. Kiemeney LALM, Straatman H, Witjes JA. Decreasing bladder cancer mortality in the Netherlands. Br J Urol 1996; 78: 686-90
3. Kiemeney LALM, Witjes JA, Verbeek ALM, et al. The clinical epidemiology of superficial bladder cancer. Observations among 1745 cases. Br J Cancer 1993; 67: 806-12
4. Lamm DL, Griffith JG. The place of intravesical chemotherapy as defined by results of prospective randomized studies (substances and treatment schemes). Prog Clin Biol Res 1992; 378: 43-53
5. Soloway MS. Selecting initial therapy for bladder cancer. Cancer 1987; 60 Suppl.: 502-13
6. American Cancer Society. Cancer facts and figures. Atlanta: American Cancer Society, 1991
7. Witjes JA, Kiemeney LALM, Oosterhof GON, et al. Prognostic factors in superficial bladder cancer. A review. Eur Urol 1992; 21: 89-97
8. Morrison DA, Murphy WM, Ford KS, et al. Surveillance of stage 0, grade 1 bladder cancer by cytology alone: is it acceptable? J Urol; 1984; 132: 672-4
9. Koontz Jr WW, Prout GR, Smith W, et al. The use of intravesical thiotepa in the management of non invasive carcinoma of the bladder. J Urol 1981; 125: 307-12
10. Thrasher JB, Crawford ED. Complications of intravesical chemotherapy. Urol Clin North Am 1992; 19: 529-39
11. Richie JP. Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 1992; 19: 521-7
12. Bouffioux C, Meijden A vd, Kurth KH, et al. Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). Prog Clin Biol Res 1992; 378: 29-42
13. MRC. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC study. Br J Urol 1985; 57: 680-5
14. Lamm DL. Long term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 1992; 19: 573-80
15. Schulman C, Robinson M, Denis L, et al. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM 26) and TUR alone. Eur Urol 1982; 8: 207-12
16. Novak R, Kern J, Fister H, et al. Effects of local chemotherapy and immunotherapy on the recurrence and progression of superficial bladder cancer. Eur Urol 1988; 14: 367-70
17. Martinez-Pineiro JA, Jimenez León J, Martinez-Pineiro L Jr, et al. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer J Urol 1990; 143: 502-6
18. Llopis B, Gallego J, Mompo JA, et al. Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors. Eur Urol 1985; 11: 73-8
19. Crawford ED, McKenzie D, Mansson W, et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: a report of six cases. J Urol 1986; 136: 668-9
20. Akaza H, Isaka S, Koiso K, et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 1987; 20: S91-95
21. Matsumura Y, Akaze H, Isaka S, et al. The 4th study of prophylactic intravesical chemotherapy with adriamycin in the treatment of superficial bladder cancer: the experience of the Japanese urological cancer research group for adriamycin. Cancer Chemother Pharmacol 1992; 30: S10-14
22. Debruyne FMJ, vd Meijden APM, Witjes JA. et al. Bacillus Calmette-Guerin versus mitomycin-C intravesical therapy in superficial bladder cancer. Results of a randomized trial after 21 months of follow up. Urology 1992, 40 Suppl.: 115
23. Witjes JA, vd Meijden APM, Witjes WPJ, et al. A randomized prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumors and primary carcinoma in situ of the urinary bladder. Intravesical instillations in superficial bladder cancer. Eur J Cancer 1993; 29A: 1672-6
24. de Groot AC, Meijden APM vd, Conemans JMH et al. Frequency and nature of cutaneous reactions to intravesical instillation of mitomycin for superficial bladder cancer. Urology 1992; 40 Suppl.: 16-9
25. Meijden APM vd, Kurth KH, Oosterlink W, et al. Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU group. Cancer Chemother Pharmacol 1992; 30: S95-98
26. Burk K, Kurth KH, Newling D. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog Clin Biol Res 1989; 303: 423-34
27. Oosterlinck W, Kurth KH, Schroder F, et al. A prospective European Organisation for Research and Treatment of Cancer Genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single Ta, T1 papillary carcinoma of the bladder. J Urol 1993; 149; 749-52
28. Walker L, Walker MC, Parris CN, et al. Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro. Urol Res 1988; 16: 329-31
29. Ohtani M, Miyanage N, Imada S, et al. Promotive effect of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice. Abstract. J Urol 1994; 151: 391A
30. Long JP, Prout Jr GR, Yau Kai Wong, et al. The effect of verapamil on multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J Urol 1990; 143: 1053-6
31. Ohi Y, Ohmori H, Shirahama T, et al. Intravesical instillation of adriamycin an the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. Cancer Chemother Pharmacol 1992; 30: S50-54
32. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3
33. Glashan RW. A randomized controlled study of intravesical a-2b-interferon in carcinoma in situ of the bladder. J Urol 1990; 144: 658-61
34. Chodak GW. Intravesical interferon treatment of superficial bladder cancer. Urology 1989; 34: 84-96
35. Corti Ortiz D, Rivera Garay P, Aviles Jasse J, et al. Profilaxis del cancer vesical superficial con 1 mg de BCG endovesical: comparacion con otras dosis. Actas Urol Esp 1993; 17: 239-42
36. Martinez-Pineiro JA, Solsona E, Flores N, et al: Improving the safety of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 Suppl. 1: 13-8
37. Pagano F, Bassi P, Piazza N, et al. Improving the efficacy of BCG immunotherapy by dose reduction. Eur Urol 1995; 27 Suppl. 1: 19-22
38. Mack D, Frick J. Five year results of a phase II study with low-dose BCG therapy in high risk superficial bladder cancer. Urology 1995; 45: 958-61
39. Witjes JA, Fransen MPH, v d Meijden APM, et al. Use of maintenance intravesical bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long term follow up of a randomised phase 2 study. Urol Int 1993; 51: 67-72
40. Witjes JA, vd Meijden APM, Debruyne FMJ. Use of intravesical Bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol Int 1990; 45: 129-36
41. Lamm DL, Stogdill VD, Stogdill BJ, et al. Complications of bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J Urol 1986; 135: 272-4
42. Lamm DL, Crissman J, Blumenstein B, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. In: Debruyne FMJ, Denis L, vd Meijden APM. editors. EORTC Genito-Urinary Group Monograph 6: BCG in Superficial bladder cancer. New York: Alan R. Liss Inc., 1989: 335-55
43. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacillus Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991; 325: 1205-9
44. Simmons WB, Reichert DF, Lucio RM, et al. Pyrimidinone Interferon Inducers in the Treatment of Murine Transitional Cell Carcinoma. J Urol 1983; 129: 169
45. Sarosdy MF, Lamm DL, Williams RD, et al. Phase 1 trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 31-3
46. Sarosdy MF, Lowe BA, Schellhammer PF, et al. Bropirimine immunotherapy of bladder CIS: positive phase II results of an oral interferon. Abstract. J Urol 1994; 151: 304A
47. Pawinski A, Bouffioux C, Sylvester R, et al. Meta-analysis of EORTC/MRC randomised clinical trials for the prophylactic treatment of Ta,T1 bladder cancer. J Urol 1996; 155: 492A
48. Akaza H, Kioso K, Kotake T, et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 1992; 30: S15-20
49. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow up. J Urol 1992; 147: 1020-3
50. Harker WG, Meyers FJ, Frieha FS, et al. Cisplatin, metotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. J Clin Oncol 1985; 3: 1463-70
51. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (metotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461-9
52. Stoter G, Splinter TAW, Child JA, et al. Combination chemotherapy with cisplatin and metotrexate in advanced transitional cell cancer of the bladder. J Urol 1987; 137: 663-7
53. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (metotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988; 139: 470-4
54. Malmstrom PU, Rintala E, Wahlqvist R, et al. Five year follow up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. J Urol 1996; 155: 1903-6
55. Hall RR. Neo-adjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial. Abstract. Proceedings ASCO 1996. J Clin Oncol 1996; 15: 244
56. Logothetis C, Swanson D, Amato R, et al. Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. J Urol 1996; 155: 1241-5
57. Skinner DG, Daniels JR, Russel CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991; 145: 459-67
58. Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996; 155: 504-5
59. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985; 133: 403-7
60. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response. Cancer 1989; 64: 2448-58
61. Logothetis CJ, Dexeus FH, Finn FH, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050-5
62. Loerher PJ, Einhorn LH, Elson PH, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma. A Cooperative group study. J Clin Oncol 1992; 10: 1066-73
63. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent of metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 244-51
64. Moore MJ, Iscoe N, Tannock IF. A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150: 1131-4
65. Logothetis C, Dieringer P, Ellerehorst J, et al. A 61% response rate with 5-fluorouracil, interferon-alpha2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc AACR 1992; 33: 221
66. Tannock I, Gospodarowicz M, Connolly J, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the princess Margaret hospital experience. J Urol 1989; 142: 289-92
67. Witjes JA, Wullink M, Oosterhof GON, et al. Toxicity and results of MVAC chemotherapy in advanced transitional cell carcinoma. Eur Urol. In press